Equities Analysts Set Expectations for Sarepta Therapeutics, Inc.’s FY2026 Earnings (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Research analysts at Zacks Research decreased their FY2026 earnings per share estimates for Sarepta Therapeutics in a report issued on Tuesday, April 23rd. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will post earnings per share of $10.13 for the year, down from their previous forecast of $11.48. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.13 per share.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.50. Sarepta Therapeutics had a negative return on equity of 18.97% and a negative net margin of 43.11%. The business had revenue of $396.80 million during the quarter, compared to analysts’ expectations of $387.18 million. During the same quarter last year, the business posted ($1.24) earnings per share. The company’s quarterly revenue was up 53.6% on a year-over-year basis.

Other equities analysts have also issued research reports about the company. Needham & Company LLC decreased their price target on Sarepta Therapeutics from $169.00 to $166.00 and set a “buy” rating for the company in a research report on Thursday, February 29th. UBS Group increased their price target on Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Evercore ISI increased their price target on Sarepta Therapeutics from $108.00 to $138.00 and gave the company an “in-line” rating in a research report on Tuesday, February 20th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $128.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Finally, Royal Bank of Canada increased their price target on Sarepta Therapeutics from $151.00 to $157.00 and gave the company an “outperform” rating in a research report on Thursday, February 29th. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $158.38.

Sarepta Therapeutics Trading Up 2.5 %

NASDAQ:SRPT opened at $127.39 on Thursday. The company has a quick ratio of 3.45, a current ratio of 3.95 and a debt-to-equity ratio of 1.32. Sarepta Therapeutics has a 1-year low of $55.25 and a 1-year high of $159.89. The firm has a market capitalization of $11.96 billion, a price-to-earnings ratio of -20.82 and a beta of 0.94. The stock has a fifty day simple moving average of $126.22 and a 200 day simple moving average of $110.43.

Insider Buying and Selling

In other news, Director Kathryn Jean Boor sold 761 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $122.93, for a total transaction of $93,549.73. Following the completion of the sale, the director now directly owns 7,516 shares of the company’s stock, valued at approximately $923,941.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Ian Michael Estepan sold 1,200 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.30, for a total transaction of $153,960.00. Following the completion of the sale, the chief financial officer now directly owns 39,114 shares of the company’s stock, valued at approximately $5,018,326.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kathryn Jean Boor sold 761 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $122.93, for a total value of $93,549.73. Following the sale, the director now directly owns 7,516 shares of the company’s stock, valued at $923,941.88. The disclosure for this sale can be found here. In the last ninety days, insiders sold 22,096 shares of company stock valued at $2,739,419. Corporate insiders own 7.40% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Principal Securities Inc. purchased a new stake in shares of Sarepta Therapeutics during the 4th quarter worth about $26,000. Mather Group LLC. acquired a new position in shares of Sarepta Therapeutics during the 1st quarter valued at about $28,000. Montag A & Associates Inc. acquired a new position in shares of Sarepta Therapeutics during the 3rd quarter valued at about $30,000. Cary Street Partners Investment Advisory LLC increased its holdings in shares of Sarepta Therapeutics by 154.0% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 154 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Sarepta Therapeutics by 37.0% during the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 87 shares during the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.